<DOC>
	<DOCNO>NCT00893997</DOCNO>
	<brief_summary>Primary aim : 1 . To determine immunologic response , use PR1-HLA-A2 tetramer assay , 4 subcutaneous ( SQ ) injection TVC-PR1 vaccine formulate Montanide ISA 51 VG follow granulocyte macrophage colony-stimulating factor ( GM-CSF ) low risk intermediate-1 myelodysplastic syndrome ( MDS ) patient . Secondary aim : 1 . To determine non-immunologic responder 4 subcutaneous ( SQ ) injection TVCPR1 vaccine formulate Montanide ISA 51 VG follow GM-CSF convert immunologic responder administer 4 additional dos TVC-PR1 vaccine formulate Montanide ISA 51 VG follow GM-CSF . 2 . To determine clinical response 4 8 subcutaneous ( SQ ) injection TVC-PR1 vaccine formulate Montanide ISA 51 VG follow GM-CSF patient low risk intermediate-1 MDS .</brief_summary>
	<brief_title>PR1 Vaccination Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>MDS cell over-produce protein find normal bone marrow cell . These protein use stimulate body 's immune system kill MDS cell . PR-1 peptide derive protein , PR1 peptide vaccine give help immune cell kill MDS cell . The vaccine give together granulocyte macrophage colony stimulate factor ( GM-CSF ) , increase production white blood cell intend increase number immune cell . Before start treatment study , `` screening test . '' These test help doctor decide eligible take part study . You bone marrow aspirate ( 1 tablespoon ) routine test special study . To collect bone marrow aspirate , area hip numb anesthetic small amount bone marrow withdrawn large needle . Blood ( 6 tablespoon ) drawn . The blood test do compare pre-treatment blood count post-treatment count , aspirate do allow comparison number MDS cell treatment . Both blood count aspirate show whether therapy successful . Women able child must negative blood pregnancy test . If find eligible take part study , receive PR-1 vaccine injection skin every 3 week . You receive total 4 vaccination . Each vaccination require 4 shot : 2 PR-1 vaccine 2 GM-CSF . GM-CSF give increase number immune cell might respond vaccine eventually kill MDS cell . PR-1 vaccine mixed montanide ISA 51 , use dissolve stabilize vaccine . Blood ( 1 tablespoon ) drawn routine test 1 time every 3 week ( 3 tablespoon ) drawn time receive vaccination follow visit length study . You bone marrow aspiration 4 week 4th 8th vaccination ( 1 tablespoon ) routine special test . These test allow researcher find number immune cell increase , whether cell able attack MDS cell , whether cell related change blood count . At time ( 13 week first PR-1 vaccine ) , immune system react vaccination , vaccination give . This avoid production immune cell might block effect cell already produce first 4 vaccination . If , time ( 13 week first PR-1 vaccine ) , immune system react drug , offer additional 4 vaccination . These additional vaccination give every 3 week . During time , blood ( 4 tablespoon ) draw every 3 week routine special testing . You take study time disease get bad intolerable side effect occur . Twenty-nine ( 29 ) week begin study , blood ( 1 teaspoon ) drawn check response vaccine . If respond , take study . If respond , continue follow . Follow-up involve monthly routine blood test ( 1 tablespoon blood ) 6 month . These do home result send M. D. Anderson . Every 3 month , return M. D. Anderson bone marrow aspirate routine blood test include special testing study . This investigational study . This vaccine authorize use research commercially available . About 30 patient take part multicenter study . About 20 patient enrol M. D. Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Must understand voluntarily sign informed consent form 2 . Age &gt; /= 18 year time signing informed consent form 3 . Must able adhere study visit schedule protocol requirement 4 . HLAA2 positive one allele 5 . Diagnosis myelodysplastic syndrome ( MDS ) must meet follow criterion 6 . FrenchAmericanBritish ( FAB ) Class Refractory anemia ( RA ) , Refractory Anemia Excess Blasts ( RAEB ) , refractory anemia ring sideroblast ( RARS ) 7 . World Health Organization ( WHO ) Classification refractory anemia ( RA ) , refractory anemia ring sideroblast ( RARS ) , refractory cytopenia multilineage dysplasia ( RCMD ) , refractory cytopenia ring sideroblast ( RCMDRS ) , refractory anemia excess blast type 1 ( RAEB1 ) 8 . Less 20 % blast marrow aspirate 9. International Prognostic Scoring System ( IPSS ) risk group Intermediate 1 transfusion dependent low risk . 10 . Both de novo therapy relate MDS eligible 11 . Eastern Cooperative Oncology Group ( ECOG ) performance status = 0 1 12 . Women childbearing potential must negative serum pregnancy test within 30 day start study drug . A woman childbearing potential sexually mature woman undergone hysterectomy naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) 13 . Male female childbearing potential must agree use adequate contraceptive method 14 . Serum bilirubin &lt; 2 mg/ml 15 . Serum creatinine &lt; /= 1.5 mg/ml 16 . Serum ALT &lt; 2 x upper normal limit 17. antineutrophil cytoplasmic antibody ( cANCA ) negative 18 . Not receive specific therapy MDS 4 week . However , supportive therapy permit . 1 . Marrow blast aspirate &gt; /= 20 % 2 . Blood blast &gt; 1 % 3 . Inaspirable bone marrow 4 . Myelosclerosis occupy &gt; 30 % marrow space 5 . Iron absence marrow examination transferrin saturation &lt; 20 % serum ferritin &lt; 50ng/ml 6 . B12 deficiency 7 . Folate deficiency 8 . History immune related hematological disorder [ i.e. , immune thrombopenia purpura ( ITP ) , autoimmune hemolytic anemia ( AIHA ) ] 9 . Other cause cytopenia relate MDS ( i.e. , GI blood loss ) 10 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form place subject unacceptable risk he/she participate study confounds ability interpret data 11 . Prior allogeneic syngeneic transplant 12 . Prior solid organ transplant 13 . Life expectancy severely limited disease MDS 14 . Pregnant lactating female 15 . Prior vaccine therapy MDS 16 . Chronic use ( &gt; 2 week ) great physiologic dos corticosteroid agent ( dose equivalent &gt; 10 mg/day prednisone ) within 30 day first day study drug treatment . ( Topical inhale corticosteroid permit ) 17 . Prior history malignancy MDS ( except basal cell squamous cell carcinoma carcinoma situ cervix breast ) unless subject free disease &gt; /= 5 year 18 . Known allergy incomplete Freund 's adjuvant 19 . Experimental therapy , cyclosporine , antithymocyte globulin , FK506 within 3 month study entry 20 . Treatment androgenic hormone , danazol , colony stimulating factor , erythropoietin , thalidomide , arsenic trioxide agent use treat MDS within four week first day study treatment 21. refractory anemia excess blast transformation ( RAEBt ) ( FrenchAmerican British ( FAB ) criterion ) refractory anemia excess blast type2 ( RAEB2 ) ( World Health Organization ( WHO ) criterion ) 22 . Chloroma 23 . Hypercalcemia 24 . Progressive viral bacterial infection . Patients eligible unless infection resolve patient remain afebrile seven day without antibiotic 25 . Cardiac disease symptomatic nature cardiac ejection fraction &lt; 40 % 26 . Symptomatic pulmonary disease FEV1 , FVC Carbon Monoxide Diffusing Capacity ( DLCO ) &lt; /= 50 % predict 27 . History Wegener 's Granulomatosis vasculitis 28 . History HIV positivity AIDS 29 . Prior history AML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>PR1 Peptide Vaccine</keyword>
</DOC>